Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Cancer Metastatic 1Hyperlipoproteinemia Type II 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 38Bevacizumab 25Cyclophosphamide 22Blood Specimen Collection 19Standard of Care 18Carboplatin 17Nivolumab 16Paclitaxel 15Exercise 15Gemcitabine 14atezolizumab 12Radiotherapy 12Pemetrexed 12Cisplatin 12Fluorouracil 11Doxorubicin 11Cetuximab 10Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Biopsy 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Prednisone 8Docetaxel 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × evolocumab × 90 days × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡